References
- American Cancer Society. Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2017. Accessed 2017 July. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.
- National Comprehensive Cancer Network. The NCCN Guidelines® Version 3. Multiple Myeloma. 2017 [cited 2017 Apr 10]. Available from: https://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf.
- Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–2825.
- Celgene Corporation. Highlights of Prescribing Information for Pomalyst. 2016 [cited 2017 Jul 7]. Available from: https://media.celgene.com/content/uploads/pomalyst-pi.pdf.
- Chen CC, Parikh K, Abouzaid S, et al. Real-World treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib. JMCP. 2017;23:236–246.
- Amgen. Highlights of Prescribing Information for Kyprolis. [cited 2017 Jul 7]; 2012. Available from: http://pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.ashx.
- Celgene Corporation. Highlights of Prescribing Information for Revlimid. 2015 [cited 2017 Jul 7]. Available from: https://media.celgene.com/content/uploads/revlimid-pi.pdf.
- Celgene Corporation. Highlights of Prescribing Information for Thalomid. [cited 2017 Jul 7]; 2017. Available from: https://media.celgene.com/content/uploads/thalomid-pi.pdf.
- Millennium Pharmaceuticals. Highlights of Prescribing Information for Velcade. [cited 2017, July 7]; 2017. Available from: http://www.velcade.com/files/pdfs/velcade_prescribing_information.pdf.
- Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statist Med. 2009;28:3083–3107.
- Kish L. Survey sampling. New York (NY): Wiley; 1965.
- Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–3679.